Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001 Nov 8;414(6860):212-6. PubMed.

Recommends

Please login to recommend the paper.

Comments

  1. This study suggests a novel mechanism by which NSAIDs might be protective in AD, and a potentially novel and selective mechanism for lowering Ab42 production. This is important because Ab42 is thought to be a critical factor initiating Ab aggregation. -- Benjamin Wolozin

    View all comments by Benjamin Wolozin

  2. The most innovative paper from 2001, which provided a novel means of
    modulating γ-secretase activity.

    View all comments by Dominic Walsh

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

News

  1. Anti-inflammatory Drugs Side-Step COX Cascade to Target Aβ
  2. CTAD: ApoE Carriers Sought for Trial of NSAID Derivative
  3. Surprise! Some γ-Secretase Modulators Work by Targeting APP
  4. Toward New Therapies
  5. Second-Generation γ-Secretase Modulator Heads to Phase 2

Therapeutics

  1. Flurizan™

Webinars

  1. Probing PPARγ? Agonists: Could Diabetes Drugs Treat Alzheimer's Disease?

Research Timeline Event

  1. Certain NSAIDs modulate γ-secretase to produce less Aβ42